All Stories

Merck KGaA fails midphase lupus trial arm, says totality of data support further development

One of Merck KGaA’s leading immunology assets has flunked the latest part of a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded further development is warranted in light of responses seen in subgroups and a recent win in another form of the disease.

Mar 7, 2025 - 14:21
 0
Merck KGaA fails midphase lupus trial arm, says totality of data support further development
One of Merck KGaA’s leading immunology assets has flunked the latest part of a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded further development is warranted in light of responses seen in subgroups and a recent win in another form of the disease.
Read More

Tags:

Previous Article

Key NLRB Changes Under the New Administration: What Employers Need to Know

Next Article

EMEA-003498-PIP01-23

Related Posts

Frazier arms Callio with $187M series A to fly Hummingbird's HER2 dual payload ADC to clinic

Frazier arms Callio with $187M series A to fly Hummingb...

Mar 3, 2025  0

Pfizer inks deal to test Summit’s white-hot bispecific with ADCs

Pfizer inks deal to test Summit’s white-hot bispecific ...

Feb 24, 2025  0

J&J's Shockwave Medical launches path-clearing Javelin lithotripsy catheter

J&J's Shockwave Medical launches path-clearing Javelin ...

Mar 6, 2025  0